Jardiance, which was approved in Europe in May of this year, was late in coming because of certain issues raised by the FDA at Boerhringer's manufacturing plant.
After a manufacturing issue scuttled their first attempt, Eli Lilly ($LLY) and Boehringer Ingelheim have won the FDA's blessing to market their new diabetes drug, a late entrant into a crowded space.
The agency approved empagliflozin, to be marketed as Jardiance, as an oral treatment for the nation's more than 26 million Type 2 diabetics. The drug works by blocking SGLT2 proteins, stopping glucose absorption in the kidney and leading the body to dispel excess sugars through the urine. In Phase III studies, Jardiance significantly reduced hemoglobin A1c--a common biomarker for diabetes--as well as body weight and blood pressure, the companies said.
The FDA's nod comes about 5 months later than Lilly and Boehringer had hoped, after some "previously observed deficiencies" at a plant belonging to the latter company led the agency to prolong its decision. The pair picked up European approval for Jardiance in May.
Original report: http://bit.ly/1tDbDNQ
Source: FierceBiotech
Related reading: http://bit.ly/1ogZAgW
Source: FierceBiotech
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen